Argenx Expands VYVGART's Horizon with Key New Data in Neurology
The biopharmaceutical group argenx announces the presentation of new clinical data for VYVGART and its drug candidates at the annual American Academy of Neurology (AAN) congress taking place in Chicago from April 18 to 22, 2026. The data focus on the expansion of VYVGART's use in severe myasthenia and chronic inflammatory demyelinating polyneuropathy (CIDP), as well as progress in other muscular neurology research programs.
Argenx presents clinical data supporting the expansion of access to VYVGART beyond its currently approved indication. The company is making progress towards its goal of extending VYVGART's reach to as many patients with severe myasthenia as possible, regardless of subtype. The new data includes results from the ADAPT OCULUS study, evaluating VYVGART in subcutaneous injection for patients with ocular myasthenia, as well as results from the ADAPT SERON study on patients seronegative for anti-AChR antibodies.
Advancing Beyond VYVGART
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Beyond VYVGART, argenx is advancing multiple therapeutic programs. Data related to VYVGART Hytrulo highlight its potential to produce early clinical improvement in patients with CIDP being treated for the first time. The company is also evaluating empasiprubart in phase 3 studies for the treatment of CIDP, and presents new data for adimanebart in congenital myasthenic syndromes.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 4 605 millions de dollars
Quarterly revenue: 4 605 millions de dollars
Revenue growth: 57,4 %
Net income: 1 344 millions de dollars
Guidance from the release
argenx remains on track to achieve its 'Vision 2030' anchored in the ambition to treat 50,000 patients globally
Risks mentioned
The risk that early stage clinical trials may not be predictive of results in later stage or large scale clinical trials
Demand and commercialization risks for argenx's products and product candidates, including new indications
Regulatory and pricing uncertainties for argenx's products and product candidates if approved
Opportunities identified
Vision 2030 targets: treat 50,000 patients globally, secure 10 labeled indications, and progress five pipeline candidates
Multiple label and indication expansions for VYVGART being pursued across additional autoimmune diseases
Next-generation FcRn molecules (ARGX-213 Phase 3-ready, ARGX-124 in Phase 1) advancing through development
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
